All.Can

Changing cancer care together

All.Can and looking at value from the patient perspective

Suzanne Wait, Managing Director The Health Policy Partnership

ICHOM congress 2019


We are a multi-stakeholder initiative aimed to improve efficiency in cancer care



All.Can international has 26 members, all of which have an equal seat at the table.

All.Can Changing cancer care together

All.Can international: our vision




All.Can was set up to find sustainable solutions to the problem of waste in cancer care. By focusing resources on what matters


most to patients, we can see greater system efficiency and better patient

outcomes

Driving national policy change: All.Can national initiatives



2017 policy report: our call to action





Building on our policy report 4 core research projects in 2018-2019

Understanding inefficiency

Measuring value

Investing in data

All.Can patient survey

Gather patient perspectives on where they encounter inefficiencies in their care – and where efficiency could be improved



iPAAC collaboration

Gather examples of best practice in improving efficiency in hospitals, and integrate them into All.Can hub of best practice



ICHOM-All.Can Value in Cancer Care project

Assess what contributes to variations in outcomes in lung and breast cancer, with a view to embedding greater efficiency and care improvement strategies



Insights into the role of data

Develop multi-stakeholder position paper on the potential role of data in driving efficiency in cancer care

(project still in scoping stage)



All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsor) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

3

Efficiency – and inefficiency – must be defined first and foremost by what matters to patients.

'People need to go back to the primary source: the patients. These are the people at the forefront of their diseases; these are the people who can provide the answers.'

> Kathy Oliver, International Brain Tumour Alliance All.Can international steering committee



All.Can Changing cancer care together

Understanding the patient perspective on efficiency: The All.Can patient survey

Nearly 4000 respondents from over 10 countries

- Current and former patients with any type of cancer, and their carers
- All cancer types, at any stage
- Questions asked about **personal experiences** with waste and inefficiency
- Questions covered the entire care continuum including financial impact of cancer
- Questionnaires developed based on in-depth interviews with patients
- Patients recruited mostly through social media and patient organisations
- Study led by Quality Health, with oversight from All.Can
- Results to be launched on 30 June 2019






Some first thoughts from the survey findings

- We should not lose sight of the importance to patients of information, ongoing support and the 'non treatment' aspects of care.
- > Addressing these 'inefficiencies' is not necessarily expensive or complicated.
- Neglecting these aspects of care, however, can compromise patients' experience of care, their outcomes and the overall efficiency of care.
- If we want to be true to our aim of delivering care focused on what matters to patients, we need to consider patient insights alongside economic and clinical data.
- These insights need to be incorporated into proposed solutions, policies and system change.

All.Can Changing cancer care together



I.Can) Changing cancer care together

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

10

Join us. Follow us. Work with us.



Changing cancer care together

Together #WeAllCan

Contact: Suzanne Wait, Suzanne.wait@hpolicy.com or secretariat@all-can.org

www.all-can.org





All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

11